New Merck & Co. LRRK2 inhibitors show good drug properties for treating Parkinson's disease March 23, 2022
Blockade of retinoic acid receptor ameliorates vision loss in preclinical retinal degeneration March 23, 2022
iTolerance raises financing to advance preclinical programs based on iTOL-100 platform technology March 22, 2022
RSS